Evidence map›Paper›PMID 38189056›Full record

ArticleAdvances in radiation oncology2024

Postoperative Radiation Therapy Is Indicated for "Low-Risk" Pathologic Stage I Merkel Cell Carcinoma of the Head and Neck Region but Not for Other Locations.

Marika M Bierma, Peter H Goff, Daniel S Hippe, Kristina Lachance, Stephanie K Schaub, Kent Wallner, Yolanda D Tseng, Jay J Liao, Smith Apisarnthanarax, Paul Nghiem and 1 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Merkel Cell Carcinoma.Hematology/oncology clinics of North America · 2024
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Marika M BiermaDepartment of Dermatology, University of Washington, Seattle, Washington.
Peter H GoffDepartment of Dermatology, University of Washington, Seattle, Washington.
Daniel S HippeFred Hutchinson Cancer Center, Biostatistics, Seattle, Washington.
Kristina LachanceDepartment of Dermatology, University of Washington, Seattle, Washington.
Stephanie K SchaubDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Kent WallnerDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Yolanda D TsengDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Jay J LiaoDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Smith ApisarnthanaraxDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
Paul NghiemDepartment of Dermatology, University of Washington, Seattle, Washington.
Upendra ParvathaneniDepartment of Radiation Oncology, University of Washington, Seattle, Washington.
University of Washington · USFred Hutch Cancer Center · US

Funding

Understand & overcome resistance to PD-1P01CA225517 · NCI · UNIVERSITY OF WASHINGTON · PI PAUL NGHIEM · 2019 to 2026
$22.7M
NCI NIH HHS P01 CA225517
6 · The paper itself

Abstract

Purpose: The role of postoperative radiation therapy (PORT) in early stage Merkel cell carcinoma (MCC) is controversial. We analyzed the role of PORT in preventing local recurrences (LR) among patients with low-risk, pathologic stage I MCC based on the location of the primary tumors: head/neck (HN) versus non-HN sites. Methods and Materials: One hundred forty-seven patients with MCC were identified that had "low risk" disease (pathologic T1 primary tumor, negative microscopic margins, negative pathologic node status, no immunosuppression or prior systemic therapy). LR was defined as tumor recurrence within 2 cm of the primary surgical bed, and its frequency was estimated with the cumulative incidence method. Results: Seventy-nine patients received PORT (30 HN, 49 non-HN) with a median dose of 50 Gy (range, 8-64 Gy) and 68 patients were treated with surgery alone (30 HN, 38 non-HN). Overall, PORT was associated with a decreased risk of LR (5-year rate: 0% vs 9.5%; Conclusions: For low-risk, pathologic stage I MCC of the extremities and trunk, excellent local control rates were achieved with surgery, and PORT is not indicated. However, PORT was associated with a significant reduction in LRs among low-risk MCC of the HN.

Identifiers

PMID38189056
PMCPMC10767274
OpenAlexW4386225894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.